SCIENTIFIC SEMINARS
April 1, 1976 March 31, 1977

Seven scientific seminars were supported by the Program during the period April 1, 1976 through March 31, 1977: three on the mainland U.S.A., two in Hawaii, and two in Japan. These seminars are listed below according to the program areas. For each seminar, the title, location, date, number of participants and observers from each country, and organizers are given.

CHEMICAL CARCINOGENESIS
Carcinogenesis and Mutagenesis of Polycyclic Aromatic Hydrocarbons, New Orleans, Louisiana, January 23-26, 1977
Organizers:
Harry V. Gelboin
Chief, Chemistry Branch, NCI
Paul Ts’o
Professor and Director, Division of Biophysics, Johns Hopkins University
Chikayoshi Nagata
Chief, Biophysics Division, National Cancer Center Research Institute
Participants and Observers:
United States 53
Japan 10

ANALYTICAL EPIDEMIOLOGY
Epidemiological Research on Cancer High Risk Groups (with special reference to the U.S.-Japan comparison of cancer patterns), Tokyo, Japan, October 8-9, 1976
Organizers:
Robert W. Miller
Head, Epidemiology Division, DCCP, NCI
Takeshi Hirayama
Head, Division of Epidemiology, National Cancer Center Research Institute
Participants and Observers:
United States 5
Japan 9

BREAST CANCER
Breast Cancer and Diet Epidemiology, Seattle, Washington, March 14-15, 1977
Organizers:
Guy R. Newell
Deputy Director, NCI
Takeshi Hirayama
Head, Division of Epidemiology, National Cancer Center Research Institute
Participants and Observers:
United States 15
Japan 7

LUNG CANCER
Multidisciplinary Treatment of Lung Cancer in an Attempt to Improve the Survival Time, Beverly Hills, California, March 1-2, 1977
Organizers:
Oleg S. Selawry
Deputy Director for Intramural Affairs, Comprehensive Cancer Center for the State of Florida at the University of Miami School of Medicine-Jackson Memorial Medical Center
Yuichi Yamamura
Professor, Department of Internal Medicine, School of Medicine, Osaka University
Participants and Observers:
United States 11
Japan 6

URINARY BLADDER CANCER
Etiology of Bladder Cancer, Kyoto, Japan, September 26-28, 1976
Organizers:
George T. Bryan
Professor, Clinical Oncology and Surgery, University of Wisconsin Center for Health Sciences
Osamu Yoshida
Professor, Department of Urology, School of Medicine, Kyoto University
Participants and Observers:
United States 7
Japan 15

CYTOLOGY
Automated Cytology, Honolulu, Hawaii, July 26-27, 1976
Organizers:
Richard A. Malmgren
Professor of Pathology, The George Washington University Medical Center
Kiyoji Kimura
Deputy Director, National Cancer Center Hospital
Participants and Observers:
United States 8
Japan 12

METASTASIS
Workshop on Metastasis-Fundamental Approaches to the Mechanism of Formation, Prevention, and Treatment, Kona, Hawaii, May 26-28, 1976
Organizers:
Philip G. Stansly
Program Director for Viral Oncology, Division of Cancer Research Resources and Centers, NCI
Haruo Sato
Professor, Research Institute for Tuberculosis, Leprosy, and Cancer, Tohoku University
Participants and Observers:
United States 11
Japan 8

HIGH LET RADIATION THERAPY
High LET Radiation Therapy Workshop, Berkeley, California, September 14-18, 1976
Organizers:
Glenn E. Sheline
Professor and Chairman of Radiation Oncology, University of California, San Francisco
Akira Tsuya
Head, Department of Radiology, Cancer Institute Hospital, Japanese Foundation for Cancer Research
Participants and Observers:
United States 14
Japan 9


SCIENTIFIC SEMINARS
April 1, 1977 March 31, 1978

Eight scientific seminars were supported by the Program during the period April 1, 1977 through March 31, 1978: two on the mainland U.S.A., two in Hawaii, and four in Japan. These seminars are listed below according to the program areas. For each seminar, the title, location, date, and the number of participants and observers from each country are given.

CHEMICAL CARCINOGENESIS
Role of DNA Repair and Misrepair in Radiation and Chemical Carcinogenesis, Kyoto, Japan, December 12-14, 1977
Organizers:
Arthur C. Upton
Director, National Cancer Institute I. Bernard Weinstein Professor of Pathology, Columbia University
Tsutomu Sugahara
Professor, Faculty of Medicine, Kyoto University
Hiraku Takebe
Professor, Faculty of Medicine, Kyoto University
Participants and Observers:
United States 8
Japan 38
Third Country 4

CANCER VIROLOGY
Origin and Function of Oncogenic Sequences in RNA Tumor Viruses, Pasadena, California, May 31-June 1, 1977
Organizers:
Yohei Ito
Professor, Faculty of Medicine, Kyoto University
Robert M. McAllister
Childrens Hospital of Los Angeles
Participants and Observers:
United States 11
Japan 8

CANCER IMMUNOLOGY
Immunology of Cancer and its Fundamental Basis, Osaka, Japan, September 16-17, 1977
Organizers:
Yuichi Yamamura
Professor, Osaka University Medical School
William D. Terry
Associate Director for Immunology, National Cancer Institute
Participants and Observers:
United States 9
Japan 27

CANCER CHEMOTHERAPY
Seminar on Antitumor Antibiotics, San Francisco, California, May 12-13, 1977
Organizers:
Stephen K. Carter
Director, Northern California Cancer Program
Yoshio Sakurai
Director, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
Participants and Observers:
United States 20
Japan 11

BREAST CANCER
Hormones and Receptors in Breast Cancer, Honolulu, Hawaii, March 6-7, 1978
Organizers:
William L. McGuire
Professor of Medicine, University of Texas Medical School, Health Science Center
Haruo Sugano
Director, Cancer Institute, Japanese Foundation for Cancer Research
Participants and Observers:
United States 11
Japan 7

LUNG CANCER
Multidisciplinary Treatment of Lung Cancer, Honolulu, Hawaii, February 1-3, 1978
Organizers:
Oleg S. Selawry
Deputy Director for Intramural Affairs, The University of Miami School of Medicine
Yuichi Yamamura
Professor, Osaka University Medical School
Participants and Observers:
United States 7
Japan 6

HIGH LET RADIATION THERAPY
High LET Radiation Therapy Workshop, Tokyo, Japan, September 29-30, 1977
Organizers:
Glenn E. Sheline
Professor and Vice-Chairman of Radiation Oncology, University of California Medical Center, San Francisco
Akira Tsuya
Head, Department of Radiology, Cancer Institute Hospital, Japanese Foundation for Cancer Research
Participants and Observers:
United States 9
Japan 25

CYTOLOGY
Automated Cytology, Hakone, Japan, April 28-29, 1977
Organizers:
Chester J. Herman
Head, Quantiative Cytology Section, Laboratory of Pathology, National Cancer Institute
Kiyoji Kimura
Vice-Director, National Cancer Center Hospital
Participants and Observers:
United States 7
Japan 10



SEMINARS AND MEETINGS
April 1976 September 1977

During the period April 1976 through September 1977, the following participants presented papers at the seminars or workshops listed below by program area.

CHEMICAL CARCINOGENESIS
International Conference on Polycyclic Hydrocarbon Carcinogenesis: Chemistry, Biology and Environment, New Orleans, Louisiana, January 23-26, 1977

UNITED STATES

• James F. Engel, Midwest Research Institute. Synthesis of 13-C-Labeled Benzo(a)pyrene Derivatives
  
• Ronald Harvey, University of Chicago. Synthesis and Properties of the Diol Epoxides of Carcinogenic Hydrocarbons
  
• Donald M. Jerina, NIAMDD. The Bay Region Theory of Hydrocarbon Carcinogenicity
  
• Melvin Calvin, University of California, Berkeley. Chemical Activation of Polycyclic Hydrocarbon
  
• Shen Yang and Harry V. Gelboin, National Cancer Institute. Mechanism of Enzymatic Conversion of Benzo(a)pyrene to Dihydrodiol and 7, 8-diol-9, 10 Epoxides: Stereo-specificity of Microsomes Mixed-Function Oxidases and Epoxide Hydratase
  
• Bernard Weinstein, Alan Jeffrey, and Dezider Grunberger, Columbia University. Modification of Nucleic Acids by Derivatives of Benzo(a)pyrene: Structural, Conformational, and Functional Aspects
  
• Peter Brookes, Chester Beatty Research Institute, England. The Chemical Nature and Biological Role of Cell Mediated Polycyclic Hydrocarbon-DNA Reactions
  
• Stephen Lesko, William Caspary, Ronald Lorentzen, and Paul Ts'o, Johns Hopkins University. Involvement of One-electron Oxidation in Benzo(a)pyrene Carcinogenesis and Involvement of Nucleus in Benzo(a)pyrene Metabolism
  
• Joseph Arcos, Tulane University. Significance of Hydrocarbon-Nitrosamine Pulmonary Syncarcinogenesis: Some Enzymological Correlates
  
• Raymond Daudel, Centre National de La Recherche Scientifique, France. The Work of Mme. Pascaline Daudel on Chemical Carcinogenesis
  
• Minor J. Coon, University of Michigan. Purified Liver Microsomal Cytochrome P-450: Characterization of Multiple Forms
  
• John C. M. Tsibiris, University of Florida. Affinity Chromatography of Microsomal Enzymes Metabolizing Aromatic Hydrocarbons
  
• James R. Gillette, National Heart and Lung Institute. The Role of Mixed-Function Oxygenases in Toxicity
  
• Ronald Estabrook, University of Texas, Dallas. Summary and Prediction: Mixed Function Oxidases and Polycyclic Hydrocarbons
  
• Charles Heidelberger, University of Southern California. Oncogenic Transformation of Cell Cultures by Polycyclic Aromatic Hydrocarbons and Their Derivatives
  
• Paul O.P. Ts'o, J. Carl Barrett, Jacques Bonnet, Brian Crawford, Robert Moyzis, and Takeki Tsutsui, Johns Hopkins University. Some Fundamental Aspects About the Mechanisms of In Vitro Neoplastic Transformation
  
• Takeo Kakunaga, National Cancer Institute. Factors Effecting In Vitro Transformation by Polycyclic Hydrocarbon: Their Relevance to the Transformation Process
  
• Wayne Levin, Hoffman-La Roche. Mutagenesis as Related to Drug Metabolism
  
• Eliezer Huberman, Oak Ridge National Laboratory. Cell Transformation and Mutability of Different Genetic Loci in Mammalian Cells by Metabolically Activated Carcinogenic Polycyclic Hydrocarbons
  
• Bruce E. Casto, Biolabs, Inc., Joseph A. Di Paolo, National Cancer Institute. Modulation of Transformation and Enhancement of Virus Transformation of Syrian Hamster Cells by Carcinogenic Polycyclic Hydrocarbons
  
• Beverly Paigen, Roswell Park Memorial Institute. The Genetics of AHH in the Human Population and its Relationship to Lung Cancer
  
• Rufus Day, National Cancer Institute. Repair of DNA Damage by Benzo(a)pyrene Diol Epoxide I
  
• Peter A. Cerutti, University of Florida. Formation and Repair of Benzo(a)pyrene Induced DNA-Damage in Mammalian Cells
  
• Tsuyoshi Kakefuda, National Cancer Institute. Binding and Structural Modification of DNA by Benzo(a)pyrene Derivatives
  
• Veronica Maher, Michigan State University. Effect of DNA Excision Repair on the Cytotoxicity and Mutagenicity of Polycyclic Hydrocarbon Metabolites in Human Cells
  
• Bernard Strauss, P. Karran, K. Bose, P. Higgins, M. Altamirano-Dimas, and K. Tatsumi, University of Chicago. Different Pathways for Excision Repair in Lymphoid Cells
  
• Daniel W. Nebert, Steven A. Atlas, and Richard E. Kouri, National Institute of Child Health and Human Development. Polycyclic Hydrocarbon-Initiated Tumorigenesis and the Ah Locus
  
• Stuart Brown, Veterans Hospital, Washington, D.C. Evidence for Linkage Between Aryl Hydrocarbon Hydroxylase Expression and Enzyme Markers Assigned to Human Chromosome 2 in Human x Mouse Hybrid Cells
  
• Curtis Harris, National Cancer Institute. Metabolism of Polycyclic Hydrocarbons by Cultured Human Tissues and Cells
  
• Paul Nettesheim, Oak Ridge National Laboratory. In Vivo-In Vitro Studies on the Evolution of Epithelial Neoplasia Induced by Carcinogenic Polycyclic Hydrocarbons
  
• Dietrich Hoffman, I. Schemeltz, K. D. Brunnemann, S.S. Hecht, and E.L. Wynder, American Health Foundation. Polynuclear Aromatic Hydrocarbons in Tobacco Carcinogenesis
  
• Stephen S. Hecht, M. Loy, R. Mazzarese, and D. Hoffman, American Health Foundation. Carcinogenicity of 5-Methylchrysene: Structure-Activity Studies of Metabolism
  
• Michael R. Guerin, Oak Ridge National Laboratory. Polynuclear Aromatic Hydrocarbons Associated with Syn-fuels Technology
  
• J. William Lloyd, United Steel Workers of America. Cancer in Workers Exposed to Polycyclic Hydrocarbons
  
• Irvin J. Selikoff, City University of New York. Polycyclic Hydrocarbons in Environmental Carcinogenesis
  
• Bernard Pullman, Institut de Biologie Physico-Chimique, France. Summary and Prediction: Chemical Aspects of Polycyclic Hydrocarbon Carcinogenesis
  
• James R. Fouts, National Institute of Environmental Health Science. Summary and Prediction: Biomedical, Environmental and Societal Aspects of Polycyclic Hydrocarbon Carcinogenesis
  

• Chikayoshi Nagata and Masahiko Kodama, National Cancer Center Research Institute, Tokyo. Physico-Chemical Studies of the Metabolism of Polycyclic Hydrocarbons
  
• Toshio Kuroki, University of Tokyo. Mutagenesis and Transformation by Polycyclic Hydrocarbons: Comparative Mutagenicity of Diolepoxide Derivatives of Hydrocarbons and Inhibition of Transformation by Protease Inhibitors
  
• Yuzuru Ishimura and O. Hayaishi, Keio University, Tokyo. Enzymes of Oxygenation
  
• Minako Nagao and Takashi Sugimura, National Cancer Center Research Institute, Tokyo. Mutagenicity of Aromatic Hydrocarbons and Their Metabolites
  
• Gonya Takahashi, Kyoto University. Excretion and Distribution of Aromatic Hydrocarbon (3-MC) in the Body
  
• Hidetsuru Matsushita, National Institute for Industrial Health, Tokyo. Analytical Method for Monitoring Polycyclic Aromatic Hydrocarbons in the Environment
  

CANCER IMMUNOLOGY
Immunotherapy of Cancer and its Fundamental Basis, Osaka, Japan, September 16-17, 1977

UNITED STATES

• Albert Lobuglio, Ohio State University. Properties of Immunopotentiators having Anti-Cancer Activity and their Mechanism of Action—monocyte tumoricidal activity in normal individuals and in patients receiving immunotherapy
  Immunotherapy of Leukemia—immunological evaluation of successfully treated lymphoma patients
  
• Herbert J. Rapp, National Cancer Institute. Properties of Immunopotentiators having Anti-Cancer Activity and their Mechanism of Action—treatment of experimental cancer by a combination of surgery and immunotherapy
  
• Steven A. Rosenberg, National Cancer Institute. Tumor Antigens—serologic analysis of murine and human sarcoma antigens
  Immunotherapy of Melanoma and Sarcoma—experience with the use of intralesional BCG in the treatment of malignant melanoma
  
• Herbert F. Oettgen, Memorial Sloan-Kettering Cancer Center. Immunotherapy of Lung, Pleura, and Breast Cancers—chemoimmunotherapy of advanced breast cancer using C. Parvum
  Immunotherapy of Leukemia—chemoimmunotherapy of acute myeloblastic leukemia (P. aeruginosa)
  
• E. Carmack Holmes, University of California, Los Angeles. Immunotherapy of Lung, Pleura, and Breast Cancers—immunology and immunotherapy of lung cancer
  
• Richard Hodes, National Cancer Institute. Mechanism of Induction and Manifestation of Immune Response against Tumor-specific Antigens—regulatory mechanisms in the generation of cell-mediated cytotoxicity in vitro
  
• Michael J. Mastrangelo, American Oncologic Hospital Fox Chase Cancer Center. Immunotherapy of Melanoma and Sarcoma—a randomized prospective trial comparing methyl-CCNU plus vincristin to methyl-CCNU plus vincristin plus BCG plus allogeneic tumor cells in patients with metastatic melanoma
  
• Hiroshi Shiku, Memorial Sloan-Kettering Cancer Center. Serological Definition of Cell Surface Antigens of Human Malignant Melanomas
  
• William Terry, National Cancer Institute. Program Coordinator and Rapporteur
  

JAPAN

• Yuichi Yamamura, Osaka University Medical School. Program Coordinator and Rapporteur
  
• Hiroshi Kobayashi, Hokkaido University School of Medicine. Tumor Antigens—recent studies regarding xenogenization of tumor cells
  
• Kokichi Kikuchi, Sapporo Medical College. Mechanism of Induction and Manifestation of Immune Response against Tumor-Specific Antigens—cellular mechanism in immune resistance to auto-chthonous and syngeneic methylcholanthrene-induced sarcomas in rats
  
• Yoshiyuki Hashimoto, Tohoku University. Properties of Immunopotentiators Having Anti-Cancer Activity and their Mechanism of Action-inhibition of drug-metabolizing enzymes in mouse after treatment with host-mediating antitumor drugs
  
• Tomio Tada, Chiba University Medical School. Mechanism of Induction and Manifestation of Immune Response Against Tumor-Specific Antigens—I region expressions on suppressor and cytotoxic T cells in tumor immunity
  
• Tadashi Yamamoto, Tokyo University, Institute of Medical Science.
  
• Toru Tokunaga, National Institute of Health, Tokyo. Properties of Immunopotentiators Having Anti-Cancer Activity and their Mechanism of Action-macrophage activation with BCG
  
• Tomiko Tanaka, National Cancer Center, Tokyo. Properties of Immunopotentiators Having Anti-Cancer Activity and their Mechanism of Action-effect of ATS, AMS and Latex particles on the therapeutic efficacy of BCG or Corynebacterium liquefaciens (Propioni-bacterium acnesC7) in syngeneic mice
  
• Kazumasa Yamada, Nagoya University Medical School. Immunotherapy of Leukemia—chemoimmunotherapy of acute myelogenous leukemia in adults with BCG-cell wall skeleton
  
• Kunzo Orita, Okayama University Medical School. Immunotherapy of Digestive Organ Cancers—immunotherapy of advanced gastric cancer and colo-rectal cancer with BCG and BCG-cell wall skeleton
  
• Tsuyoshi Ogura, Osaka University Medical School. Immunotherapy of Lung, Pleura and Breast Cancers-immunotherapy with BCG-cell wall skeleton in patients with neoplastic pleurisy
  
• Masayasu Kitagawa, Osaka University Medical School. Properties of Immunopotentiators Having Anti-Cancer Activity and their Mechanism of Action—preventive effect of BCG-cell wall skeleton on chemical carcinogenesis with dimethylbenzanthrancene
  
• Kosei Yasumoto, Kyushu Cancer Center. Immunotherapy of Lung, Pleura and Breast Cancers—immunotherapy of lung cancer and carcinomatous pleuritis

CANCER VIROLOGY
Symposium on Origin and Function of Oncogenic Sequences in RNA Tumor Viruses, Pasadena, California, May 31-June 1, 1977

UNITED STATES

• Robert M. McAllister, Childrens Hospital of Los Angeles. Infectivity of Cat and Baboon Type C Virus-Related Genes
  
• Norman Davidson, California Institute of Technology. Electron Microscope Studies of RNA Tumor Virus Genomes
  
• Murray Gardner, University of Southern California. RD-114 and FeLV Gene Expression in Spontaneous Feline Neoplasia
  
• Peter Vogt, University of Southern California.
  
• Arthur Frankel, National Cancer Institute. The Nature and Distribution of the Moloney Sarcoma Virus Genome
  
• Deborah Spector, University of Southern California.
  
• Edward Scolnick, National Cancer Institute. Mapping of Kirsten Sarcoma Virus Genome
  
• Peter Besmer, Massachusetts Institute of Technology. Endogenous Virus-Like Sequences in Mouse Cells
  
• Peter Duesberg, University of Southern California. The Genetic Map of Rous Sarcoma Virus
  
• Hidesaburo Hanafusa, Rockefeller University. Messages of Avian RNA Tumor Viruses
  
• Michael Bishop, University of California. The Genesis of a Viral Transforming Gene

JAPAN

• Hiroshi Yoshikura, University of Tokyo. The Pseudotype of Mouse Hepatitis Virus Encoated in Murine Leukemia Virus Envelope
  
• Kumao Toyoshima, Osaka University. Modification of Avian Sarcoma Virus by Quail Cell Passage
  
• Tsutomu Miyamoto, Nagasaki University. Quantitative Detection of an Endogenous Viral Function by Using Pseudotype Virus Formation of Vesicular Stomatitis Virus
  
• Yohei Ito, Kyoto University. Possible Activation of C-Type Particles During “Progression” of the Chemically Induced Pulmonary Tumors in Mice
  
• Mitsuaki Yoshida, National Cancer Center Research Institute. Transformation-Defective Mutants of Avian Sarcoma Viruses: Transformation of Fibroblasts and Expression of src-Related Sequences

METASTASIS
Workshop on Metastasis: Fundamental Approaches to the Mechanism of Formation, Prevention, and Treatment, Kona, Hawaii, May 26-28, 1977

UNITED STATES

• J. Martin Brown, Stanford University Medical Center. Treatment of Metastatic Disease—The Effect of Radiation and Chemotherapeutic Agents on the Incidence and Treatment of Metastatic Cancer
  
• Isaiah J. Fidler, Frederick Cancer Research Center. General Mechanisms of Tumor Metastasis
  Concluding Remarks on Biology of Metastasis-Role of the Host
  
• Bernard Fisher, University of Pittsburgh Medical School. Treatment of Metastatic Disease—Clinical and Experimental Observations in the Treatment of Metastatic Disease
  
• Pietro M. Gullino, National Cancer Institute. Host Responses and Metastasis—Release of Neoplastic Cells by Mammary Tumors
  
• Alfred S. Ketcham, University of Miami School of Medicine. Control of Metastasis-Metastatic Potential in Neoplastic Disease
  
• Untae Kim, Roswell Park Memorial Institute. Host Responses and Metastasis—Pathogenesis of Spontaneously Metastasizing Tumors: Simulation of Possible Carcinogenic Process in Man
  
• Garth L. Nicolson, University of California. Tumor Cell Characteristics and Metastasis—Cell Surface Properties of Metastatic Tumors
  Concluding Remarks on Biology of Metastasis—Role of the Tumor
  
• Robert Pollack, State University of New York at Stony Brook. Tumor Cell Characteristics and Metastasis—Some Recent Advances in Cell Biology: Relevance to Metastasis
  
• Philip G. Stansly, National Cancer Institute. Concluding Remarks on Biology of Metastasis-Consideration of Future Efforts of U. S.-Japan Program on Matastasis
  
• Jan Vaage, Pondville Hospital, Walpole, Mass. Control of Metastasis—Free Tumor Antigen and Immune Serum Factors in Control of Metastasis
  
• Leonard Weiss, Roswell Park Memorial Institute. Tumor Cell Characteristics and Metastasis—Cell Detachment in Relation to Metastasis

JAPAN

• Tsuneo Baba, Kyushu University Medical School, Fukuoka. Treatment of Metastatic Disease—A Novel Approach to Experimental Chemotherapy of Cancer and Metastasis
  
• Takao Kodama, Hokkaido University Medical School, Sapporo. Host Responses and Metastasis—Pathology of Immunologic Repression of Tumor Metastasis in Lymph Nodes
  
• Kyuya Nakamura, Fukushima Medical College, Fukushima. Host Responses and Metastasis—Electron-Microscopic Studies on Extravasation of Tumor Cells
  
• Haruo Sato, Tohoku University, Sendai. Tumor Cell Characteristics and Metastasis—Deformability and Variability of Tumor Cells by Transcapillary Passage with Reference to Organ Affinity
  
• Keiichi Suemasu, National Cancer Center Institute. Control of Metastasis—Dextran Sulfate Ester, as an Inhibitor of Cancer Metastasis
  
• Kenzo Tanaka, Kyushu University Medical School, Fukuoka. Host Responses and Metastasis—Tumor Metastasis and Thrombosis, with Special Reference to Platelet Aggragation
  
• Eiro Tsubura, Tokushima University Medical School, Tokushima. Control of Metastasis—Effects of Sulfated Polysaccharide on Bloodborne Pulmonary Metastasis in the Rats
  
• Shigeru Tsukagoshi, Cancer Chemotherapy Center, Cancer Institute, Tokyo. Treatment of Metastatic Disease—Fundamental Approaches for the Chemotherapy of Lymph Node Metastasis

LUNG CANCER
Third Joint Seminar on Lung Cancer, Los Angeles, California, March 1-2, 1977

UNITED STATES

• Oleg S. Selawry, Comprehensive Cancer Center, University of Miami. Morphology as Guideline for Differential Therapy
  Multidisciplinary Treatment of Lung Cancer (III) and the Special Case of Small Cell Anaplastic Carcinoma—Miami Protocols
  
• Hamar D. Brereton, National Cancer Institute.
  
• Heine H. Hansen, Finsen Institute, Copenhagen. Multidisciplinary Treatment of Lung Cancer (III) and the Special Case of Small Cell Anaplastic Carcinoma—WHO Subclassification, Extent of Disease, and Therapeutic Response
  
• Ariel Hollinshead, George Washington University. Multidisciplinary Treatment of Lung Cancer (II)—Specific and Nonspecific Immunotherapy, and Experience with Tumor Associated Antigens
  
• E. Carmack Holmes, University of California, Los Angeles. Multidisciplinary Treatment of Lung Cancer (II)—Immuno-Prognosis and Nonspecific Immunotherapy
  
• William McGuire, National Cancer Institute. Multidisciplinary Treatment of Lung Cancer (I)—Adjuvant Studies Including Chemotherapy
  Multidisciplinary Treatment of Lung Cancer (II)
  
• Clifton Mountain, M. D. Anderson Hospital. Multidisciplinary Treatment of Lung Cancer (I)
  
• Alan Ng, University of Miami School of Medicine. Morphology as Guideline for Differential Therapy—Reliability of the Cytologic Diagnosis by Cell Type
  
• Carlos Perez, Washington University, St. Louis. Multidisciplinary Treatment of Lung Cancer (I)—Adjuvant Treatment Including Radiotherapy
  
• Raymond Yesner, Yale University School of Medicine. Morphology as Guideline for Differential Therapy—Reliability of the Modified WHO Classification of Lung Cancer and Subclassification of Small Cell Carcinoma
  
• Robert Omata, National Cancer Institute.

JAPAN

• Yuichi Yamamura, Osaka University Hospital. Multidisciplinary Treatment of Lung Cancer (I)—Immunologic Therapy with BCG Cell Wall Skeleton
  
• Shoji Hattori, Osaka University. Multidisciplinary Treatment of Lung Cancer (III) and the Special Case of Small Cell Anaplastic Carcinoma—Treatment of Small Cell Carcinoma: Relations Between Cell Type and Response to Treatment
  
• Yoshihiro Hayata, Tokyo Medical College. Multidisciplinary Treatment of Lung Cancer (III) and the Special Case of Small Cell Anaplastic Carcinoma—multidisciplinary Treatment of Lung Cancer in Japan
  
• Yukio Shimosato, National Cancer Center Hospital, Tokyo. Morphology as Guideline for Differential Therapy—Reevaluation of Histologic Classification for Treatment of Lung Cancer and Morphologic Behavior of Oat-Cell Carcinoma in Nude Mice
  
• Takeshi Yoneyama, National Cancer Center Hospital, Tokyo. Multidisciplinary Treatment of Lung Cancer (II)—Combined Surgical Treatment
  
• Nimoru Nishimura, Aichi Cancer Center Hospital, Nagoya. Multidisciplinary Treatment of Lung Cancer (I)—Simultaneous Combination Treatment with Radiotherapy and Chemotherapy

BREAST CANCER
United States-Japan Breast Cancer, Diet, and Epidemiology Meeting, Seattle, Washington, March 14-15, 1977

UNITED STATES

• John L. Young, National Cancer Institute. Time-Trend Data (Basic Epidemiology)—In United States: Blacks
  
• Max Myers, National Cancer Institute. Time-Trend Data (Basic Epidemiology)—In United States: Whites
  
• John J. Mulvihill, National Cancer Institute. Special Populations—Familial Aggregations of Breast Cancer
  
• William Blot, National Cancer Institute. Special Populations—Geographic Patterns of Breast Cancer in the United States
  
• William Kidwell, National Cancer Institute. Experimental Correlates—Dietary Lipids: Cancer Cell Cultures as Experimental Models
  
• Seoras D. Morrison, National Cancer Institute. Experimental Correlates—Breakdown of Control of Feeding in Experimental Tumor Growth
  
• Sidney Abraham, National Center for Health Statistics, Rockville, Md. Diet—Hormone—Disease Chain—Definition of Dietary Components—Dietary Intake of Women 18 to 74 Years of Age in the United States, 1971-1974
  
• Robert R. Omata, National Cancer Institute.
  
• Ernst L. Wynder, American Health Foundation. Diet—Hormone—Disease Chain—Effect that Diet and Hormones have on the Etiology of Breast Cancer
  
• Roger R. Williams, University of Utah. Diet—Hormone—Disease Chain—Dietary Factors which can Promote Cancer by Way of Hormonal Path ways
  
• Robert Schneider, University of California, Davis. Experimental Correlates An Age-Standardized Rate Comparison of Breast Cancer Expression in Man, Dog, and Cat
  
• Malcolm C. Pike, Cancer Research Project, Los Angeles, California. Diet—Hormone—Disease Chain—Population Differences in Hormones
  
• Nathaniel I. Berlin, Northwestern University Medical School. Experimental Correlates
  
• F. de Waard, Nederlandse Organisatie Voor De Kankerbestrijding, Amsterdam, Netherlands. Time-Trend Data Outside the U. S. and Japan

JAPAN

• Haruo Sugano, Japanese Foundation for Cancer Research. Diet—Hormone—Disease Chain
  Time-Trend Data (Basic Epidemiology)—In Japan
  
• Goi Sakamoto, Cancer Institute, Japanese Foundation for Cancer Research. Special Populations—Familial Aggregations of Breast Cancer
  
• Nobuaki Sasano, Tohoku University, Sendai. Special Populations—Migrant Studies
  
• Yasuaki Nishizuka, Aichi Cancer Center, Nagoya. Experimental Correlates—Biological Influence of Fat on Breast Cells
  
• Minako Nagao, National Cancer Center Research Institute. Diet—Hormone—Disease Chain—Special Dietary Factors
  
• Yasuo Kagawa, Jichi Medical College, Tochigi-Ken. Diet—Hormone—Disease Chain—Definition of Dietary Components—Dietary Intake of Women 18 to 74 Years of Age for Japan, 1971-1974
  
• Takeshi Hirayama, National Cancer Center Research Institute. Diet—Hormone—Disease Chain—Effect that Diet and Hormones have on the Etiology of Breast Cancer Special Populations

CANCER THERAPY
Symposium on Antitumor Antibiotics, San Francisco, California, May 12-13, 1977

UNITED STATES

• Martin Apple, University of California, San Francisco. Anthracycline Antitumor Antibiotics—The Multidisciplinary Drug Research Group of the NCCP and its Approach to Anthracyclines
  
• Robert Benjamin, M. D. Anderson Hospital. Anthracycline Antitumor Antibiotics—Adriamycin and Other Compounds Under Study in the U. S.
  
• Vincent Bono, National Cancer Institute. Principles for Obtaining and Evaluating Antineoplastic Antibiotics—Preclinical Status of Macromomycin at the National Cancer Institute
  
• Stephen K. Carter, Northern California Cancer Program, Palo Alto. Antitumor Antibiotics—Some Thoughts for the Future
  
• Robert Comis, Upstate Medical Center, Syracuse, N.Y. Antitumor Antibiotics of Major Interest—Neocarzinostatin—U.S. Experience
  
• Stanley Crooke, Bristol Laboratories, Syracuse, N.Y. Antitumor Antibiotics of Major Interest—Bleomycin—Bleomycin Clinical Pharmacology
  
• John Daniels, Stanford Medical Center. Antitumor Antibiotics of Major Interest—Anthracycline Antitumor Antibiotics—The Endomyocardial Biopsy Technique to Evaluate Anthracycline Cardiac Toxicity
  
• Hugh Davis, National Cancer Institute. Antitumor Antibiotics in Perspective-Antitumor Antibiotics and their Role in Current Oncologic Practice
  
• Henry Dion, Parke-Davis Co., Detroit, Michigan. Principles for Obtaining and Evaluating Antineoplastic Antibiotics—Fingerprint Methods Used to Identify Known Antineoplastic Agents in Culture Filtrates
  
• John Douros, National Cancer Institute. Principles for Obtaining and Evaluating Antineoplastic Antibiotics—Present National Cancer Institute’s Fermentation Development Program
  
• Michael Friedman, University of California, San Francisco. Antitumor Antibiotics of Major Interest—Bleomycin—The U. S. Experience
  
• Abraham Goldin, National Cancer Institute. Principles for Obtaining and Evaluating Antineoplastic Antibiotics—Criteria for Selection of New Analogs on Antitumor Antibiotics
  
• Asger Langlykke, Frederick Cancer Research Center. Principles for Obtaining and Evaluating Antineoplastic Antibiotics—Microbial Process Translation: Laboratory to Pilot Plant at the Frederick Cancer Center
  
• Franco Muggia, National Cancer Institute. The Clinical Evaluation of New Antitumor Antibiotics
  
• Gary Neil, Upjohn Co., Kalamazoo, Michigan. Principles for Obtaining and Evaluating Antineoplastic Antibiotics—Detection and Assay of Antitumor Antibiotics
  
• John Rosazza, University of Iowa. Principles for Obtaining and Evaluating Antineoplastic Antibiotics—Antitumor Antibiotic Bioactivation, Biotransformation and Derivation by Microbial Systems
  
• Philip Schein, Georgetown University Hospital. Antitumor Antibiotics of Major Interest—Mitomycin C— The U. S. Experience with Emphasis on Combinations for Gastric Cancer
  
• Saul Schepartz, National Cancer Institute. Principles for Obtaining and Evaluating Antineoplastic Antibiotics—Historical Overview of the National Cancer Institute’s Fermentation Program
  
• Milan Slavik, Georgetown University Hospital. Antitumor Antibiotics of Major Interest—New Compounds Under Development and Clinical Evaluation—United States
  
• John Venditti, National Cancer Institute. Principles for Obtaining and Evaluating Antineoplastic Antibiotics-—In Vivo Antitumor Evaluation of Antibiotics

JAPAN

• Yoshio Sakurai, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research. Antitumor Antibiotics of Major Interest—New Compounds Under Development and Clinical Evaluation—Japan
  
• Hamao Umezawa, National Institutes of Health, Tokyo. Principles for Obtaining and Evaluating Antineoplastic Antibiotics—New Microbial Secondary Metabolites Under Preclinical Development for Cancer Treatment
  
• Mitsuyuki Abe, Kyoto University. Antitumor Antibiotics of Major Interest—Bleomycin—The Combined Use of Bleomycin with Radiation in the Treatment of Cancer
  
• Hisashi Furue, Teikyo University School of Medicine, Tokyo. Antitumor Antibiotics of Major Interest—Anthracycline Antitumor Antibiotics— The Clinical Study of A clacinomycin and Adriamycin
  
• Ikuro Kimura, Okayama School of Medicine. Antitumor Antibiotics of Major Interest—Anthracycline Antitumor Antibiotics—Neocarzinostatin-Clinical Studies in Japan
  
• Yoshiyuki Koyama, National Medical Center Hospital, Tokyo. Antitumor Antibiotics in Perspective—A Summary of the Clinical Data on Antibiotics in Japan
  Antitumor Antibiotics of Major Interest—Mitomycin C—The Current Status of the Chemotherapy of Gastric Cancer in Japan with Special Emphasis on Mitomycin C
  
• Akira Matsuda, Nippon Kayaku Co., Ltd., Tokyo. Antitumor Antibiotics of Major Interest—Bleomycin—New Bleomycin Analogs
  
• Tadaaki Miyamoto, National Institute of Radiological Science, Chiba. Antitumor Antibiotics of Major Interest—Bleomycin—The Combined Use of Bleomycin with Mitomycin in the Treatment of Advanced Cancers
  
• Makato Ogawa, Aichi Cancer Center Hospital, Nagoya.
  
• Kiyoshi Watanabe, Kanegafuchi Chemical Industry Co., Takasago. Principles for Obtaining and Evaluating Antineoplastic Antibiotics—Preclinical Study of Macromomycin
  
• Naoki Yamanaka, Aichi Cancer Center Research Institute, Nagoya. Antitumor Antibiotics of Major Interest—Bleomycin—Experimental and Clinical Results with the Combination of Bleomycin plus Mitomycin

CYTOLOGY
United States-Japan Seminar on Cancer Cytology, Honolulu, Hawaii, July 26-27, 1976

UNITED STATES

• Judith Prewitt, National Institutes of Health. Mathematics of Assessment of Progress in Cytology Automation
  
• Myron R. Melamed, Memorial Sloan-Kettering Cancer Center. Global Features for High Resolution Information from Flow Cytometry New Approaches
  
• Paul F. Mullaney, Los Alamos Scientific Laboratory. Flow System Instrumentation as Applied to Cervical Cytology
  
• Leon Wheeless, University of Rochester Medical Center. Multistage Slit-Scan Prescreening System Specimen Collection and Preparation Slide Versus Flow
  
• Chester Herman, National Institutes of Health. Potential Applicability of New Cytochemical Probes in Cytology Automation
  Cooperative Studies—Sample Exchange Self Administered “Pap Test?”
  
• Richard L. Malmgren, George Washington University Medical Center. Instrument Development Evaluation Protocol
  
• Peter Bartels, University of Arizona. Computer Assessment of Lymphocyte Populations
  
• Ronald Jensen, Lawrence Livermore Laboratory, University of California. Cytochemical Markers for Multiparameter Flow Analysis Applied Toward Diagnosis of Cervical Carcinoma

JAPAN

• Kiyoji Kimura, National Cancer Center Hospital. Nucleolar Findings of Cancer Cells and its Application to Automated Cytology
  
• Yoshio Tenjin, Kyoundou Hospital, Tokyo. Autocytology Screening by Image Processing Method Using MELCOM7700
  
• Yoshio Uei, National Cancer Center Hospital. High Speed Cytoscreening System for the Uterine Cancer with Cell Type Dependent Hierarchial Algorithm
  
• Yoshio Hashimoto, College of Medical Technology, Kansai. Further Improvement of Autocytoscreener and the Field Test with it
  
• Noboru Tanaka, Chiba Cancer Center Research Institute. Field Testing on Screening of Uterine Cervical Cancer Utilizing CYBEST
  
• Morio Onoe, University of Tokyo. Present Status of Automated Online Microscope
  
• Tadashi Sugishita, Kyoundou Hospital.
  
• Makoto Ogawa, Aichi Cancer Center Hospital.
  
• Yoshihiko Kishigami, Osaka Hospital, Center for Adults Disease.
  
• Iwao Nishiya, Hokkaido University.
  
• Tokuhiro Kikuchi, Sapporo Hospital, Hokkaido.
  
• Ryuichi Suzuki, Central Research Laboratory, Hitachi Co., Ltd.

Cytology Workshop, Hakone, Japan, April 28-29, 1977

UNITED STATES

• Paul Mullaney, Los Alamos Scientific Laboratory. Multiparameter Flow Analysis: Recent LASL Experience in Automated Cytology
  
• Doran Klingler, University of Utah Research Institute. Evaluation Criteria for Automated Cell Analyzers for Cancer Screening
  
• Ronald Jensen, Lawrence Livermore Laboratory University of California. Two New Parameters for Automated Diagnosis—One for Flow Analysis and One for Static Analysis
  
• Thomas Sharpless, Memorial Hospital for Cancer and Allied Diseases, New York. Handling Flow Cytophotometric Data by Computer
  
• Judith Prewitt, National Institutes of Health.
  
• Myron R. Melamed, Memorial Sloan-Kettering Cancer Center.
  
• Peter Bartels, University of Arizona.

JAPAN

• Shoji Hattori, Osaka Hospital, Center for Adults Disease. Specimen Preparation for Auto-Cytoscreener
  
• Yoshio Tenjin, Kyoundou Hospital, Tokyo. Classification of Atypical Squamous Cells Into 32 Types for Purpose of Automated Image Analysis and Their Correlation with DNA Contents
  Automatic Prescreening Systems Combined Total Fluorometry and Image Analysis in Cytology
  
• Noboru Tanaka, Chiba Cancer Center Research Institute. Field Testing of CYBEST System: Experimental Practical Use for Mass Screening
  
• Yoshio Hashimoto, College of Medical Technology, Kansai. Evaluation of Smears for Auto-Cytoscreener
  
• Yoshio Uei, National Cancer Center. Specimen Preparation for Automated Uterine Cervical Cytology
  
• Iwao Nishiya, Hokkaido University School of Medicine. Cytophotometry With Fiber Optic System in an Approach Toward Practical Use
  
• Yoshihiko Kishigami, Osaka Hospital, Center for Adults Disease. Specimen Preparation for Auto-Cytoscreener
  
• Masayoshi Takahashi, Central Hospital, Japanese National Railway. Preliminary Report of Laser Scanning Fluorometer
  
• Yoshio Noguchi, Electotechnical Laboratory, Tokyo. A Segmentation Method of Cellular Images Using Color Information
  
• Kiyoji Kimura, National Cancer Center Hospital.

URINARY BLADDER CANCER
Etiology of Bladder Cancer, Kyoto, Japan, September 26-28, 1976

UNITED STATES

• George T. Bryan, University of Wisconsin. Role of Tryptophan in Bladder Carcinogenesis
  
• Charles King, National Center Toxicological Research, Arkansas. Chemical Carcinogenesis to the Bladder
  
• M. R. Melamed, Memorial Hospital for Cancer and Allied Disease, New York. Urinary Cytology in Occupational Bladder Cancer—Cytologic Studies of Carcinogenesis in the Human Urinary Bladder
  
• A. M. Pamukcu, University of Wisconsin. Bladder Carcinogenesis by Bracken Fern-Carcinogenesis of Bracken
  
• Walter Troll, New York University Medical Center. Environmental Factors in the Etiology of Bladder Cancer
  
• Gerald M. Lower, Jr., University of Wisconsin. Bladder Cancer Epidemiology and Genetic Factors—Metabolic/Genetic Factors Involved in Human Urinary Bladder Carcinogenesis
  
• Samuel M. Cohen, Nagoya City University Medical School, Exchange Scientist, United States-Japan Cooperative Research Program.

JAPAN

• Osamu Yoshida, Kyoto University, Kyoto. Etiology of Bladder Cancer: From Clinical Aspects-Strategy for Etiological Study of Bladder Cancer
  
• Masahi Okada, Tokyo Biochemical Research Institute. Chemical Carcinogenesis to the Bladder—Urinary Bladder Carcinogenesis by Nitrosamines
  
• Mitsuo Watanabe, National Institute of Hygienic Science. Role of Tryptophan in Bladder Carcinogenesis— The Study of Carcinogenic Tryptophan Metabolites
  
• Iwao Hirono, Faculty of Medicine, Gifu University. Bladder Carcinogenesis by Bracken Fern
  
• T. Niijima, Okayama University. Etiology of Bladder Cancer from Clinical Aspect
  
• Sumiko Ishizu, Tokyo Women's Medical College. Urinary Cytology in Occupational Bladder Cancer—The Occupational Bladder Tumor Problem in the Dye Industry of Japan
  
• Takashi Yamada, Dokkyo University School of Medicine, Tochigi. Urinary Cytology in Occupational Bladder Cancer—Two Different Types of Cancer Development in the Urothelium of the Human Urinary Bladder with Different Prognosis
  
• Takeshi Hirayama, National Cancer Center Research Institute. Bladder Carcinogenesis by Bracken Fern—Epidemiology of Cancer of the Esophagus in Miye, Nara, and Wakayama Prefecture with Special Reference to the Role of Bracken Fern
  Environmental Factors in the Etiology of Bladder Cancer—Cigarette Smoking and Urinary Bladder Cancer: Results of a Prospective Study for 265,118 Adults Aged 40 and Above in Japan
  
• Kunio Aoki, Aichi Cancer Center Research Institute, Nagoya University. Bladder Cancer Epidemiology and Genetic Factors—Epidemiology of Bladder Cancer Deaths in Japan
  
• Junichi Ushijima, Hokkaido University, Hokkaido. Bladder Carcinogenesis by Bracken Fern and Isolation of the Carcinogenic Factor
  
• Masae Tatematsu, Nagoya City University Medical School. Etiology of Bladder Cancer: From Clinical Aspects—Comparative Histopathology of Bladder Cancer in Japan and the United States

HIGH LET RADIATION THERAPY
High LET Radiation Therapy Seminar, Berkeley, California, September 14-18, 1976

UNITED STATES

• Glenn E. Sheline, University of California, San Francisco. Current Status of High LET Radiotherapy in the United States
  
• Peter R. Almond, University of Texas, Houston. A Review on the Status of Physics Dosimetry with Particular Reference to the Intercomparison on United States-Japanese Beams During 1976
  
• Eric Hall, Columbia University. Radiobiological Intercomparisons In Vivo and In Vitro
  
• David Hussey, M. D. Anderson Hospital. Radiotherapy with Fast Neutrons
  
• Simon Kramer, Thomas Jefferson University Hospital, Philadelphia. Development of Randomized Clinical Protocols in the United States
  
• Theodore Phillips, University of California Medical Center. Role of Whole Body Scanner in Treatment Planning
  
• Cornelius-Tobias, University of California, Berkeley. 2-D Images Using Heavy Ions
  
• S. Derenzo. Transverse Section Imaging Using Positron Emitters for Tumor Localization
  
• Ronald Huesman. Conversion of Attenuation Coefficient to Electron Density
  
• Kenneth Crowe. 3-D Images Using Heavy Ions

JAPAN

• Akira Tsuya, Japanese Foundation for Cancer Research. Current Status of High LET Radiotherapy in Japan
  
• Sadayoshi Fukumoto, National Laboratory for High Energy Physics. Present Status of the KEK Proton Synchrotron and Layout of 500 MeV Booster Beam Line for High LET Radiation Therapy
  
• Tetsuo Inada, National Institute for Radiological Sciences, Chiba. United States-Japan Intercomparison of Neutron Dosimetry
  
• Muneyasu Urano, National Institute for Radiological Sciences, Chiba. The Biological Properties of the NIRS Cyclotron Neutrons
  
• S. Morita and Y. Umegaki, National Institute for Radiological Sciences, Chiba. Radiotherapy with Fast Neutrons in Japan
  
• T. Iinuma, National Institute for Radiological Sciences, Chiba. Nuclear Medicine Diagnostic Instrumentation and Techniques

High LET Radiation Therapy Workshop, Tokyo, Japan, September 29-30, 1977

UNITED STATES

• Simon Kramer, Thomas Jefferson University Hospital, Philadelphia. Development of Clinical Trials with Fast Neutrons—Development of Clinical Trials, Achievements, Problems and Randomization Where do we go from here? —Common Protocols for Clinical Trials with Particles?
  
• Lester Peters, M. D. Anderson Hospital. Biologic Equation of United States and Japanese Neutron Rads—Evolution of Dose Schedules at United States Neutron Facilities
  Development of Clinical Trials with Fast Neutrons—Current Status of and Problems Experienced with Neutron Protocols, Including Selection of Control Patients, Treatment Schedules, and Mixed Beams
  
• William E. Powers, Thomas Jefferson University Hospital, Philadelphia. Where do we go from here? —Clinical Import of Particle Therapy in the United States
  
• Eric J. Hall, College of Physicians and Surgeons, Columbia University. Japan-United States Fast Neutron Beams—Current Status of the United States-Japanese Fast Neutron Beam Biological Dosimetry Studies
  Biologic Equation of United States and Japanese Neutron Rads—Biological Basis for Deriving Biologically Equivalent Rads Between the United States and Japan
  
• Glenn E. Sheline, University of California, San Francisco.
  
• Peter R. Almond, University of Texas, Houston. United States and Japan Fast Neutron Beams—Current Status of the United States-Japanese Fast Neutron Beam Dosimetry Intercomparisons
  Biologic Equation of United States and Japanese Neutron Rads—Physical Basis for Deriving Biologically Equivalent Rads Between the United States and Japan
  Where do we go from here?—Clinical Import of Particle Therapy
  
• Theodore L. Phillips, University of California, San Francisco. Particles Other Than Neutrons for Radiation Therapy—The Biologic and Physical Properties of Accelerated Heavy Particles from Helium to Argon and a Comparison to Neutron Effects
  Where do we go from here?— The Next Particle After Neutrons
  
• Herman D. Suit, Massachusetts General Hospital.
  
• Hermann A. Grunder, Lawrence Berkeley Laboratory.

JAPAN

• Akira Tsuya, Cancer Institute Hospital, Tokyo.
  
• Yoichiro Umegaki, National Institute of Radiological Sciences, Chiba. Development of Clinical Trials with Fast Neutrons—Fast Neutron Therapy Protocols in Japan
  Where do we go from here?—Proposal on the Hospital-Based Therapy Oriented Particle Accelerators
  
• Shigefumi Okada, Tokyo University School of Medicine.
  
• Masashi Hashizume, National Institute of Radiological Sciences, Chiba.
  
• Shinji Takahashi, Hamamatsu Medical College.
  
• Eisei Tazaki, Tokyo Woman's Medical College.
  
• Tetsuji Nishikawa, National Laboratory of High Energy Physics, Ibaragi.
  
• Sadayoshi Fukumoto, National Laboratory of High Energy Physics, Ibaragi. Where do we go from here?—Possible Utilization of KEK Booster Beam for Medical Applications
  
• Akira Ito, Tokyo University Institute of Medical Sciences. United States and Japan Fast Neutron Beams—Neutron Dosimetry Intercomparison Between IMS and United States
  
• Daiju Matsuzawa, Tohoku University, Sendai.
  
• Hisai Yamashita, Keio University School of Medicine, Tokyo.
  
• Tetsuo Inada, National Institute of Radiological Sciences, Chiba. Particles Other Than Fast Neutrons for Radiation Therapy
  
• Ikuo Watanabe, National Institute of Radiological Sciences, Chiba. Japan-United States Fast Neutron Beams—Biological Experiments and Results of Fast Neutron Beams in Japan
  
• Shozo Suzuki, Tokyo University Institute of Medical Sciences. Japan-United States Neutron Beams—Biological Dosimetry in Japan
  
• Hiroshi Tsunemoto, National Institute of Radiological Sciences, Chiba. Development of Clinical Trials with Fast Neutrons—Clinical Trial with 30 MeV d-Be Neutrons at NIRS Hospital
  
• Shinroku Morita, National Institute of Radiological Sciences, Chiba. Development of Clinical Trials with Fast Neutrons—Result of Fast Neutron Therapy for Carcinoma of the Uterine Cervix T3 and T4A
  
• Yuzuru Kutsutani, National Institute of Radiological Sciences, Chiba.
  
• Tadayoshi Matsuda, Metropolitan Komagome Hospital, Tokyo.
  
• Katsuhiro Kawashima, National Institute of Radiological Sciences, Chiba. United States and Japan Fast Neutron Beams—Some Problems Experienced with Neutron Dose Intercomparison at the NIRS
  
• Osamu Hara, Nippon University, Tokyo. Where do we go from here?—Project Plan of Pi-Meson Cancer Therapy Facility at the Nihon University
  
• Mitsuyuki Abe, Kyoto University School of Medicine.
  
• Yasuo Hirao, Tokyo University Institute for Nuclear Study.
  
• Yasushi Shigematsu, Osaka University School of Medicine.
  
• Akira Kurisu, National Institute of Radiological Sciences, Chiba.
  
• Toshio Kitagawa, National Cancer Center Hospital.

ANALYTICAL EPIDEMIOLOGY
Workshop on Analytical Epidemiology, Tokyo, Japan, October 8-9, 1976

UNITED STATES

• R. W. Miller, National Cancer Institute. Cancer High Risk Groups: A Review
  
• S. M. Cohen, St. Vincent's Hospital, Worchester. Epidemiology of Urinary Bladder Cancer
  
• G. T. Bryan, University of Wisconsin. Epidemiology of Urinary Bladder Cancer
  
• I. M. Moriyama, Radiation Effect Research Foundation, Hiroshima. Cancer Mortality in Japan and in the United States
  
• J. Norman, Radiation Effect Research Foundation, Hiroshima. Epidemiology of Breast Cancer in Hiroshima

JAPAN

• T. Hirayama, National Cancer Center Research Institute. Comparative Epidemiology of Cancer in Japan and in the United States
  
• N. Kobayashi, Tokyo University. Immune Deficiency Registry
  
• K. Ohmi, Tokyo University. Childhood Cancer in Japan. Clinical Epidemiology
  
• K. Aoki, Nagoya University. Childhood Cancer in Japan. Descriptive Epidemiology
  
• K. Miyake, Sapporo Medical College. Epidemiology of Childhood Leukemia in Hokkaido
  
• Y. Ozaki, Shiga University, Moriyama. Herpes Type Two Virus and Cervical Cancer
  
• J. Sawada, Kyoto Medical College. Herpes Type Two Virus and Cervical Cancer
  
• H. Kato, Radiation Effect Research Foundation, Hiroshima. Radiation and Cancer: A Review